Which has stronger earnings and valuation, SCNX or CLNN?

Clene has lower revenue, but higher earnings than Scienture. Clene is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scienture $430K 29.94 -$41.51M -$2.10 N/A Clene $200K 282.53 -$26.17M -$3.50 N/A

Is SCNX or CLNN more profitable?

Scienture has a net margin of 0.00% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Scienture's return on equity. Company Net Margins Return on Equity Return on Assets Scienture N/A -53.51% -42.47% Clene -20,063.96% N/A -137.04%

Is GRCE or SCNX more profitable?

Grace Therapeutics' return on equity of -36.11% beat Scienture's return on equity. Company Net Margins Return on Equity Return on Assets Grace Therapeutics N/A -36.11% -34.39% Scienture N/A -53.51% -42.47%

Do analysts prefer RYM or SCNX?

Scienture has a consensus target price of $1.50, indicating a potential upside of 378.47%. Given Scienture's stronger consensus rating and higher probable upside, analysts clearly believe Scienture is more favorable than RYTHM. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Scienture 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, RYM or SCNX?

RYTHM has higher revenue and earnings than Scienture. RYTHM is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RYTHM $17.28M 2.83 -$33.26M -$10.53 N/A Scienture $430K 29.94 -$41.51M -$2.10 N/A

Is RYM or SCNX more profitable?

Scienture has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. RYTHM's return on equity of -12.57% beat Scienture's return on equity. Company Net Margins Return on Equity Return on Assets RYTHM -6.20% -12.57% -2.60% Scienture N/A -53.51% -42.47%

Which has higher valuation & earnings, SCYX or SCNX?

SCYNEXIS has higher revenue and earnings than Scienture. SCYNEXIS is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SCYNEXIS $20.60M 2.15 -$8.61M -$2.09 N/A Scienture $430K 29.94 -$41.51M -$2.10 N/A

Is SCYX or SCNX more profitable?

Scienture has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -44.15% beat Scienture's return on equity. Company Net Margins Return on Equity Return on Assets SCYNEXIS -41.79% -44.15% -32.61% Scienture N/A -53.51% -42.47%

Do analysts recommend SCNX or AGFY?

Scienture presently has a consensus target price of $1.50, suggesting a potential upside of 378.47%. Given Scienture's stronger consensus rating and higher probable upside, analysts plainly believe Scienture is more favorable than Agrify. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scienture 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Agrify 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, SCNX or AGFY?

Scienture has higher earnings, but lower revenue than Agrify. Agrify is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scienture $430K 29.94 -$41.51M -$2.10 N/A Agrify $12.26M 3.66 -$41.75M -$22.65 N/A

Is SCNX or AGFY more profitable?

Scienture has a net margin of 0.00% compared to Agrify's net margin of -424.11%. Scienture's return on equity of -53.51% beat Agrify's return on equity. Company Net Margins Return on Equity Return on Assets Scienture N/A -53.51% -42.47% Agrify -424.11% -185.90% -72.67%

Scienture (SCNX) Competitors

$0.31 +0.00 (+0.10%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.31 0.00 (-0.16%)

As of 09/18/2026 07:42 PM Eastern

Compare

SCNX vs. CLNN, GRCE, RYM, SCYX, and AGFY

Should you buy Scienture stock or one of its competitors? Scienture's main competitors and comparable companies include Clene (CLNN), Grace Therapeutics (GRCE), RYTHM (RYM), SCYNEXIS (SCYX), and Agrify (AGFY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Scienture compare to Clene?

Scienture (NASDAQ:SCNX) and Clene (NASDAQ:CLNN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

In the previous week, Clene had 2 more articles in the media than Scienture. MarketBeat recorded 2 mentions for Clene and 0 mentions for Scienture. Scienture's average media sentiment score of 0.00 equaled Clene'saverage media sentiment score.

Company	Overall Sentiment
Scienture	Neutral
Clene	Neutral

Scienture currently has a consensus price target of $1.50, suggesting a potential upside of 378.47%. Clene has a consensus price target of $34.00, suggesting a potential upside of 681.61%. Given Clene's stronger consensus rating and higher possible upside, analysts clearly believe Clene is more favorable than Scienture.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scienture	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Scienture has a beta of 3.25, meaning that its share price is 225% more volatile than the broader market. Comparatively, Clene has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

5.7% of Scienture shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 21.4% of Scienture shares are owned by company insiders. Comparatively, 28.3% of Clene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Scienture has a net margin of 0.00% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Scienture's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scienture	N/A	-53.51%	-42.47%
Clene	-20,063.96%	N/A	-137.04%

Clene has lower revenue, but higher earnings than Scienture. Clene is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scienture	$430K	29.94	-$41.51M	-$2.10	N/A
Clene	$200K	282.53	-$26.17M	-$3.50	N/A

Summary

Clene beats Scienture on 9 of the 15 factors compared between the two stocks.

How does Scienture compare to Grace Therapeutics?

Grace Therapeutics (NASDAQ:GRCE) and Scienture (NASDAQ:SCNX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Grace Therapeutics has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market. Comparatively, Scienture has a beta of 3.25, meaning that its stock price is 225% more volatile than the broader market.

Grace Therapeutics has higher earnings, but lower revenue than Scienture. Grace Therapeutics is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A
Scienture	$430K	29.94	-$41.51M	-$2.10	N/A

In the previous week, Grace Therapeutics had 2 more articles in the media than Scienture. MarketBeat recorded 2 mentions for Grace Therapeutics and 0 mentions for Scienture. Grace Therapeutics' average media sentiment score of 1.03 beat Scienture's score of 0.00 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Grace Therapeutics	Positive
Scienture	Neutral

Grace Therapeutics presently has a consensus price target of $6.00, indicating a potential upside of 184.36%. Scienture has a consensus price target of $1.50, indicating a potential upside of 378.47%. Given Scienture's higher possible upside, analysts clearly believe Scienture is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Scienture	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 5.7% of Scienture shares are held by institutional investors. 10.8% of Grace Therapeutics shares are held by company insiders. Comparatively, 21.4% of Scienture shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Grace Therapeutics' return on equity of -36.11% beat Scienture's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-36.11%	-34.39%
Scienture	N/A	-53.51%	-42.47%

Summary

Grace Therapeutics beats Scienture on 7 of the 12 factors compared between the two stocks.

How does Scienture compare to RYTHM?

RYTHM (NASDAQ:RYM) and Scienture (NASDAQ:SCNX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

RYTHM has higher revenue and earnings than Scienture. RYTHM is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYTHM	$17.28M	2.83	-$33.26M	-$10.53	N/A
Scienture	$430K	29.94	-$41.51M	-$2.10	N/A

Scienture has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. RYTHM's return on equity of -12.57% beat Scienture's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
Scienture	N/A	-53.51%	-42.47%

RYTHM has a beta of 9.44, indicating that its stock price is 844% more volatile than the broader market. Comparatively, Scienture has a beta of 3.25, indicating that its stock price is 225% more volatile than the broader market.

In the previous week, RYTHM's average media sentiment score of 0.00 equaled Scienture'saverage media sentiment score.

Company	Overall Sentiment
RYTHM	Neutral
Scienture	Neutral

Scienture has a consensus target price of $1.50, indicating a potential upside of 378.47%. Given Scienture's stronger consensus rating and higher probable upside, analysts clearly believe Scienture is more favorable than RYTHM.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Scienture	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

6.0% of RYTHM shares are owned by institutional investors. Comparatively, 5.7% of Scienture shares are owned by institutional investors. 3.5% of RYTHM shares are owned by insiders. Comparatively, 21.4% of Scienture shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Scienture beats RYTHM on 8 of the 14 factors compared between the two stocks.

How does Scienture compare to SCYNEXIS?

SCYNEXIS (NASDAQ:SCYX) and Scienture (NASDAQ:SCNX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

Scienture has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -44.15% beat Scienture's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-41.79%	-44.15%	-32.61%
Scienture	N/A	-53.51%	-42.47%

SCYNEXIS has higher revenue and earnings than Scienture. SCYNEXIS is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.60M	2.15	-$8.61M	-$2.09	N/A
Scienture	$430K	29.94	-$41.51M	-$2.10	N/A

In the previous week, SCYNEXIS had 1 more articles in the media than Scienture. MarketBeat recorded 1 mentions for SCYNEXIS and 0 mentions for Scienture. SCYNEXIS's average media sentiment score of 0.00 equaled Scienture'saverage media sentiment score.

Company	Overall Sentiment
SCYNEXIS	Neutral
Scienture	Neutral

SCYNEXIS currently has a consensus target price of $33.00, indicating a potential upside of 639.91%. Scienture has a consensus target price of $1.50, indicating a potential upside of 378.47%. Given SCYNEXIS's stronger consensus rating and higher probable upside, equities analysts clearly believe SCYNEXIS is more favorable than Scienture.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Scienture	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

54.4% of SCYNEXIS shares are held by institutional investors. Comparatively, 5.7% of Scienture shares are held by institutional investors. 4.1% of SCYNEXIS shares are held by company insiders. Comparatively, 21.4% of Scienture shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

SCYNEXIS has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, Scienture has a beta of 3.25, indicating that its share price is 225% more volatile than the broader market.

Summary

SCYNEXIS beats Scienture on 10 of the 15 factors compared between the two stocks.

How does Scienture compare to Agrify?

Scienture (NASDAQ:SCNX) and Agrify (NASDAQ:AGFY) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

In the previous week, Scienture's average media sentiment score of 0.00 equaled Agrify'saverage media sentiment score.

Company	Overall Sentiment
Scienture	Neutral
Agrify	Neutral

Scienture presently has a consensus target price of $1.50, suggesting a potential upside of 378.47%. Given Scienture's stronger consensus rating and higher probable upside, analysts plainly believe Scienture is more favorable than Agrify.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scienture	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Agrify	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

5.7% of Scienture shares are held by institutional investors. Comparatively, 6.0% of Agrify shares are held by institutional investors. 21.4% of Scienture shares are held by company insiders. Comparatively, 2.2% of Agrify shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Scienture has higher earnings, but lower revenue than Agrify. Agrify is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scienture	$430K	29.94	-$41.51M	-$2.10	N/A
Agrify	$12.26M	3.66	-$41.75M	-$22.65	N/A

Scienture has a beta of 3.25, indicating that its share price is 225% more volatile than the broader market. Comparatively, Agrify has a beta of 9.96, indicating that its share price is 896% more volatile than the broader market.

Scienture has a net margin of 0.00% compared to Agrify's net margin of -424.11%. Scienture's return on equity of -53.51% beat Agrify's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scienture	N/A	-53.51%	-42.47%
Agrify	-424.11%	-185.90%	-72.67%

Summary

Scienture beats Agrify on 11 of the 14 factors compared between the two stocks.

Get Scienture News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCNX vs. The Competition

Export

Metric	Scienture	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.87M	$12.47B	$7.24B	$13.19B
Dividend Yield	N/A	2.64%	2.57%	12.81%
P/E Ratio	-0.15	797.25	275.49	25.40
Price / Sales	29.94	753.62	646.01	89.45
Price / Cash	N/A	86.36	76.25	51.42
Price / Book	0.18	10.53	10.46	6.33
Net Income	-$41.51M	$2.82B	$3.49B	$358.33M
7 Day Performance	-9.89%	1.69%	0.59%	1.12%
1 Month Performance	-33.55%	0.24%	-1.74%	-2.39%
1 Year Performance	-64.89%	3.95%	18.13%	5.35%

Scienture Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCNX Scienture	2.3629 of 5 stars	$0.31 +0.1%	$1.50 +378.5%	-64.9%	$12.87M	$430K	N/A	9	Short Interest Decrease
CLNN Clene	1.6183 of 5 stars	$3.86 -4.0%	$34.00 +780.8%	-31.9%	$51.65M	$200K	N/A	100	High Trading Volume
GRCE Grace Therapeutics	1.9052 of 5 stars	$2.14 -4.0%	$6.00 +180.4%	-31.9%	$46.91M	N/A	N/A	N/A	News Coverage Positive News
RYM RYTHM	0.4229 of 5 stars	$20.88 -2.5%	N/A	N/A	$46.69M	$17.28M	N/A	140
SCYX SCYNEXIS	2.1614 of 5 stars	$4.11 -6.4%	$33.00 +702.9%	-50.2%	$43.68M	$20.60M	N/A	60

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SCNX) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scienture (SCNX) Competitors